Drug Guidance

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant

-

Drug guidance

Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer

-

Drug guidance

Eplontersen and vutrisiran for hereditary transthyretin amyloidosis with polyneuropathy

-

Drug Guidance

Maribavir for treating refractory or drug-intolerant cytomegalovirus infection after transplant

-

Drug guidance

Nirsevimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season

-

Drug guidance

Vutrisiran for transthyretin amyloid cardiomyopathy

-

Drug guidance

Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma

-

Drug Guidance

Nusinersen and risdiplam for treating spinal muscular atrophy

Drug guidance

Tislelizumab for untreated HER2-negative, unresectable advanced gastric or gastroesophageal junction adenocarcinoma

-

Drug guidance

Elacestrant for ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation

Drug guidance